Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis (NVS) Could Be a Great Choice
12:58pm, Tuesday, 14'th Mar 2023
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Here's Why Novartis (NVS) is a Strong Value Stock
11:25am, Thursday, 09'th Mar 2023
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Large Drug Stocks to Watch as Sector Picks Up in 2023
09:11am, Thursday, 09'th Mar 2023
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sa
Novartis: Cautiously Optimistic, Hold
07:31pm, Monday, 06'th Mar 2023
Several of Novartis' blockbuster drugs are nearing patent expiry, but the company's late-stage pipeline and new drug launches could offset any revenue losses. Organizational restructuring and focus on
NVS vs. LLY: Which Stock Is the Better Value Option?
12:48pm, Friday, 03'rd Mar 2023
NVS vs. LLY: Which Stock Is the Better Value Option?
After Plunging -7.17% in 4 Weeks, Here's Why the Trend Might Reverse for Novartis (NVS)
11:18am, Wednesday, 01'st Mar 2023
The heavy selling pressure might have exhausted for Novartis (NVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
Novartis Crosses Below Key Moving Average Level
11:06am, Tuesday, 28'th Feb 2023
In trading on Tuesday, shares of Novartis crossed below their 200 day moving average of $85.10, changing hands as low as $84.78 per share. Novartis shares are currently trading off about 0.6% on the d
Novartis names Firmenich CEO as chairman designate of Sandoz
01:34am, Monday, 20'th Feb 2023
Novartis on Monday announced the appointment of Gilbert Ghostine as chairman-designate of Sandoz, the generics unit Novartis wants to spin off later this year.
Competition Coming For AbbVie's Blockbuster Humira
01:08am, Thursday, 16'th Feb 2023
It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
06:02pm, Tuesday, 14'th Feb 2023 Benzinga
Cantor Fitzgerald has initiated coverage on MoonLake Immunotherapeutics AG (NASDAQ: MLTX) with an Overweight rating and a price target of $23.
MoonLake's lead program Sonelokimab or SLK (IL-17A
Incyte (INCY) Reports Positive Long-Term Data From HS Study
05:14pm, Monday, 13'th Feb 2023 Zacks Investment Research
Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.
This High-Yielding Blue Chip Stock Is a Strong Buy
02:25pm, Monday, 13'th Feb 2023 The Motley Fool
This big pharma company pays a market-topping dividend to shareholders.
This High-Yielding Blue Chip Stock Is a Strong Buy
09:25am, Monday, 13'th Feb 2023
This big pharma company pays a market-topping dividend to shareholders.
Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy
04:03pm, Friday, 10'th Feb 2023 Zacks Investment Research
Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.
Pharmaceutical companies losing patent protection as competition grows
03:34pm, Thursday, 09'th Feb 2023
The Wall Street Journal's Jared Hopkins joins 'Power Lunch' to discuss biotech patent protection duration, competition coming to the pharmaceutical industry and pharmaceutical M&A plans.
